West Nile Fever
9
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
22.2%
2 terminated out of 9 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients
Treatment of West Nile Virus With MGAWN1
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
Phase I Study of West Nile Virus Vaccine
Vaccine to Prevent West Nile Virus Disease
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease